Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Futamura Chemical UK Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, with MCDONOUGH, JAMES E serving as the busiest examiner with 1 pending action. The portfolio is situated within 2 distinct art units, indicating that the cases are being reviewed by different specialized divisions.
The distribution of 2 actions among 2 distinct examiners suggests a varied perspective across the portfolio. Because the 2 actions are spread across 2 art units, the company's biotechnology technologies are being evaluated under different departmental standards and supervisory oversight. This balance of 2 examiners for 2 actions prevents any single person from controlling the entire pending portfolio, although the busiest examiner, MCDONOUGH, JAMES E, still handles 1 of the cases. This structure allows the company to navigate the Biotechnology & Pharmaceuticals field through multiple examiner interactions while maintaining a presence in 2 distinct art units. The 2 pending office actions represent the current active workload for this entity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDONOUGH, JAMES E | 1 | 71.2% | +10.9% |
| CALANDRA, ANTHONY J | 1 | 62.9% | +18.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596600 | EXTRACTION METHOD | CALANDRA, ANTHONY J | 410d overdue |
| 18559250 | DEVICE AND METHOD FOR TISSUE STAINING QUALITY CONTROL | MCDONOUGH, JAMES E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17596600 | EXTRACTION METHOD | CALANDRA, ANTHONY J | 410d overdue |
| 18559250 | DEVICE AND METHOD FOR TISSUE STAINING QUALITY CONTROL | MCDONOUGH, JAMES E | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| 1748 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559250 | DEVICE AND METHOD FOR TISSUE STAINING QUALITY CONTROL | MCDONOUGH, JAMES E | 1634 | §102§103 | Final Rejection | — | Pending | Nov 06, 2023 |
| 17596600 | EXTRACTION METHOD | CALANDRA, ANTHONY J | 1748 | §102§103§112 | Final Rejection | 410d overdue | Pending | Dec 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFutamura Chemical UK Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
James E Mcdonough has the most, with 1 of Futamura Chemical UK Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
